ReviewMediators of inflammation2017
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics.
Review in Mediators of inflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression.The Journal of infection · 2021Pooled it
- Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era.Frontiers in medicine · 2021Pooled it
- Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2020Pooled it
- Pooled it
- Biologic readiness: Improving tuberculosis screening in an adult allergy and immunology clinic.The journal of allergy and clinical immunology. Global · 2026Article
- Case-Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2026Review
- Non-TNF-targeted drugs in rheumatic diseasescombined with latent tuberculosis infection.Clinical and experimental medicine · 2026Review
- Integrated multi-omics analysis indicates MARCO and ZBTB20 as candidate biomarkers in rheumatoid arthritis and tuberculosis.Frontiers in immunology · 2026Article
- Tuberculosis incidence in patients treated with secukinumab - a real-world study in Brazil.Advances in rheumatology (London, England) · 2025Observational
- Retrospective analysis of systemic lupus erythematosus patients with latent tuberculosis infection: A 5-year follow-up study.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Article
- Evaluating Secukinumab as Treatment for Axial Spondyloarthritis and Psoriatic Arthritis in Patients with Comorbidities: Multicenter Real-Life Experience.Journal of clinical medicine · 2025Article
- Prevalence and Risk Factors of Latent Tuberculosis Infection Detected by IGRA in Patients with Immune-Mediated Inflammatory Diseases Before and During Biologic DMARD Therapy (TITAN Study).Journal of clinical medicine · 2025Article
- Incidence and Clinical Characteristics of Active Tuberculosis in Psoriasis Patients From a High-Burden Setting: An 18-Year Retrospective Study of 86 Patients.Experimental dermatology · 2025Article
- Latent Tuberculosis Infection in Inflammatory Rheumatic Diseases Before Biological and Synthetic DMARD Treatment: Results from Three Rheumatology Centers in Different Regions of Türkiye.Thoracic research and practice · 2025Article
- Hepatic tuberculosis induced by rituximab treatment for C1q nephropathy with minimal change disease: a case report.Frontiers in medicine · 2025Article
- Risk of tuberculosis disease in patients receiving TNF-α antagonist therapy: A meta-analysis of randomized controlled trials.New microbes and new infections · 2024Review
- Applications of Biological Therapy for Latent Infections: Benefits and Risks.International journal of molecular sciences · 2024Review
- Article
- [Influence of underlying disease and immunosuppression on the immunocompetence in inflammatory rheumatic diseases].Zeitschrift fur Rheumatologie · 2024Review
- Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.American journal of clinical dermatology · 2024Observational
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) still represents an important issue for public health in underdeveloped countries, but the use of antitumor necrosis factor agents (anti-TNF) for the treatment of inflammatory rheumatic disorders has reopened the problem also in countries with low TB incidence, due to the increased risk of TB reactivation in subjects with latent tuberculosis infection (LTBI). Over the last 5 years, several non-anti-TNF-targeted biologics have been licensed for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. We reviewed the epidemiology of TB, the role of different cytokines and of the immune system cells involved in the immune response against TB infection, the methods to detect LTBI, and the risk of TB reactivation in patients exposed to non-anti-TNF-targeted biologics. Given the limited role exerted by the cytokines different from TNF, as expected, data from controlled trials, national registries of biologics, and postmarketing surveillance show that the risk of TB reactivation in patients receiving non-anti-TNF-targeted biologics is negligible, hence raising the question whether the screening procedures for LTBI would be necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.